Muscarinic Receptors as Targets for Metronomic Therapy in Ovarian Cancer
Open Access
- 30 December 2023
- journal article
- research article
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 25 (3) , 225-230
Abstract
Aim: In this study, the effects of muscarinic acetylcholine receptor (mAChR) agonist carbachol on the proliferation of cisplatin-resistant (A2780cis) and cisplatin-free (SKOV-3) ovarian cancer cell line were for the first time investigated to further evaluate the potential therapeutic effect of metronomic chemotherapy. Material and Methods: The inhibitory effect of carbachol on cell proliferation was detected using the xCELLigence Real-Time Cell Analyzer (RTCA) dual plate (DP) system. A preliminary study was conducted to determine the dose of carbachol 100 µM, cisplatin 1 µM, and two combination studies were carried out with 100 µM carbachol + cisplatin 1 µM and 100 µM carbachol + 10 µM atropine, over cancer cells without drugs was used as the control group. The cell proliferation curve was monitored for 96 hours. The cell index value of inhibition in cell proliferation was automatically measured every hour for each well using RTCA 1.2.1 software. Results: Co-administration of carbachol with cisplatin caused a decrease in cell number in both A2780cis and SKOV-3 cell lines in a time-dependent manner (pKeywords
This publication has 19 references indexed in Scilit:
- Metronomic therapy for gynecologic cancersTaiwanese Journal of Obstetrics and Gynecology, 2012
- Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian CancerMolecular Cancer Therapeutics, 2010
- Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian CancerMolecular Cancer Therapeutics, 2010
- G-protein-coupled receptors and cancerNature Reviews Cancer, 2007
- Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian CancerCancer Research, 2007
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Muscarinic Receptors in Cell Lines from Ovarian Carcinoma: Negative Correlation with Survival of PatientsGynecologic Oncology, 2002
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJournal of Clinical Investigation, 2000
- Characterisation of muscarinic cholinergic receptors in human ovaries, ovarian tumours and tumour cell linesEuropean Journal of Cancer, 1993
- Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes.Proceedings of the National Academy of Sciences, 1991